EBESANAR
Live / Registered — Registered (as of 13 Aug 2024)
What this means for you
Registered since 13 Aug 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79365162
- Registration number
- 7470205
- Mark type
- Stylized text
- Filed
- 07 Dec 2022
- Published for opposition
- 28 May 2024
- Registered
- 13 Aug 2024
- Attorney of record
- Sean K. Owens
Goods and services
- Class 001 — Chemicals: Stem cells for scientific use; stem cells for research use; cell growth media for growing cells for scientific use; stem cells other than for medical or veterinary purposes, namely, stem cells for aesthetic purposes excluding all medical or veterinary purposes
- Class 005 — Pharmaceuticals: Drugs for medical purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for treating skin disorders; diagnostic agents, namely, diagnostic radiopharmaceutical agent for use in PET imaging; pharmaceutical preparations, namely, pharmaceutical preparations for treating skin disorders; preparations for medical purposes, namely, pharmaceutical preparations for treating skin disorders; preparations for biomedical purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical cell preparations for treating skin disorders; substances for medical use, namely, pharmaceutical preparations for treating skin disorders; substances for biomedical purposes, namely, pharmaceutical preparations for treating skin disorders; live implants for pharmaceutical purposes, namely, implants comprising living tissue for pharmaceutical purposes; biochemical and chemical products for medical use, namely, pharmaceutical preparations for treating skin disorders; biochemical and chemical products for pharmaceutical purposes, namely, pharmaceutical preparations for treating skin disorders; biochemical and chemical diagnostic preparations for medical purposes; proteins for medical purposes, namely, protein arrays for medical diagnosis purposes; biological preparations for medical and veterinary purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical and veterinary preparations for external and systemic use, namely, pharmaceutical preparations for treating skin wounds; biological, pharmaceutical and veterinary preparations for skin care for medical purposes, namely, pharmaceutical preparations for treating skin disorders; medical dressings; preparations for wound treating and healing, namely, pharmaceutical preparations for treating skin wounds; pharmaceutical preparations for treating skin wounds; stem cells for medical purposes; stem cells for veterinary purposes; somatic stem cell therapeutics, namely, somatic stem cells for medical or veterinary use; cells for medical use in the nature of fibroblasts for medical purposes; cells for medical use in the nature of fibroblasts for surgical beauty purposes; pharmaceutical implants, namely, implantable pharmaceutical preparations for treating cancer; cells for medical use in the nature of surgical implants derived from stem cells; cells for medical use in the nature of surgical implants derived from fibroblasts; cells for medical use in the nature of biological tissue for implantation; growth media for culturing cells for medical purposes; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, living cells for medical use; biotechnologically engineered tissue products, namely, cells for medical use
- Class 042 — Scientific and technological services: Pharmaceutical drug development; scientific and technological services, namely, scientific research in the field of genetics; research and development services in the fields of cell diagnostics, cell therapy; scientific research for medical purposes in the field of genetics; stem cell research services; scientific research; scientific research and development; scientific research, testing and analysis services in the field of genetics; medical research; biomedical research services; research and development in the field of biotechnology; research and development in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development of new products; industrial process research, namely, research and development of new products; research and development of new products for the pharmaceutical industry; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information about medical and scientific research for pharmaceutical products; preparation of reports relating to scientific research
- Class 044 — Medical, beauty and agricultural services: Medical services; medical diagnostic testing, monitoring and reporting services; medical assistance; health clinic services; hospital services; plastic and cosmetic surgery; medical therapies, namely, providing laser therapy for treating medical conditions; medical services in the field of regenerative medicine; medical services relating to the cultivation and procurement of stem cells; medical services in connection with the cultivation and procurement of stem cells
Owner
Prosecution history
- 22 Feb 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 04 Feb 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 03 Feb 2025 — FINAL DISPOSITION PROCESSED
- 13 Nov 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 13 Aug 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 13 Aug 2024 — REGISTERED-PRINCIPAL REGISTER
- 28 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 May 2024 — PUBLISHED FOR OPPOSITION
- 08 May 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Apr 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Apr 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Apr 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Apr 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 13 Nov 2023 — REFUSAL PROCESSED BY IB
- 24 Oct 2023 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB